Just after the Lunar New Year, in addition to the craze to have children in the United States, another undercurrent of "going to the United States to seek children" is surging-more and more families seeking assisted reproduction are turning their attention to the other side of the Pacific. Recently, B1/B2 visa reservations at U.S. consulates in Beijing, Shanghai and other places have been particularly tight, and many applicants have clearly filled in "medical consultation" in the visa purpose column. Behind this lies China families 'pursuit of more cutting-edge IVF technology and legal environment, and the U.S. reproductive market in 2026 will also show new changes that deeply match this demand.
Technological progress is the core of attracting overseas customers.
Technological progress is the core of attracting overseas customers. In addition to the already mature third-generation test tube (PGT) genetic screening, for example, embryo culture technology has significantly increased the proportion of high-quality blastocysts cultured to days 5-6, which provides more potential "seeds" for transplantation. More cutting-edge is that artificial intelligence (AI) has begun to assist embryologists in screening embryos with the most development potential, reducing differences in human judgment and making choices more "smarter".
For families traveling across oceans, a clear and stable legal environment is crucial.
For families traveling across the ocean, the clarity and stability of the legal environment are crucial. Some states in the United States, represented by California, continue to introduce and improve laws related to assisted reproduction, providing clear legal protection and enforcement frameworks for gamete (sperm, egg) donations, embryo ownership, and third-party assisted pregnancy contracts. This legal "certainty" solves greater worries for international customers and has become a key factor beyond the appeal of pure technology.
As demand grows, the market structure of U.S. reproductive centers is also refining.
As demand grows, the market landscape of U.S. reproductive centers is also being refined. Data shows that organizations likeINCINTA Fertility Center, with a large number of cycles and a high proportion of Chinese customers, have formed unique advantages with their bilingual teams, cultural understanding and full-process services. At the same time, different institutions have their own strengths in areas they are good at (such as difficult cases such as older egg activation and repeated transplant failures), prompting customers to change from "looking for American clinics" to "looking for a team of experts."
Today's test tube trip to the United States is far more than just a medical act.
Today's trip to the United States for IVF is far more than just a medical procedure. In order to meet the needs of international customers, the industrial chain is becoming increasingly perfect. In addition to medical care itself, professional consultation connecting China and the United States, accommodation and transportation arrangements during their stay in the United States, legal and financial support, and even post-transplant psychological care all form part of the "one-stop" service. Payment methods are also more flexible, and the emergence of multiple financial solutions attempts to reduce the immediate financial pressure on families.
In 2026, IVF in the United States is evolving from a high-end medical option to a systematic solution that combines cutting-edge technology, legal protection and in-depth services. It reflects families' higher pursuit of fertility quality and choice on a global scale. For families considering this path, in addition to focusing on success rate numbers, an in-depth understanding of the target organization's technical expertise, legal compliance and service ecosystem will become a more important part of making rational decisions.